Comparing three induction chemotherapy regimens for patients with locoregionally advanced nasopharyngeal carcinoma based on TNM stage and plasma Epstein–Barr virus DNA level

Table 4 Multivariable analysis of prognostic factors for IVa-b patients with EBV DNA level ≥ 1500 copies/ml

	Hazard ratio* (95% CI)	P value
Progression-free survival
Age (y) (≥ 45 vs. < 45)	1.171(0.802–1.710)	0.414
Gender(F vs. M)	1.421(0.857–2.357)	0.173
Clinical stage (IVb vs. IVa)	1.275(0.870–1.870)	0.213
IC regimen; PF vs. TPF	1.657(1.079–2.544)	0.021
IC regimen; TP vs. TPF	3.222(1.917–5.416)	< 0.001
Overall survival
Age (y) (≥ 45 vs. < 45)	1.895(0.941–3.817)	0.074
Gender(F vs. M)	0.689(0.320–1.485)	0.342
Clinical stage (IVb vs. IVa)	0.814(0.401–1.651)	0.568
IC regimen; PF vs. TPF	2.608(1.180–5.762)	0.018
IC regimen; TP vs. TPF	3.117(1.051–9.244)	0.040
Locoregional relapse-free survival
Age (y) (≥ 45 vs. < 45)	0.868(0.466–1.617)	0.594
Gender(F vs. M)	1.513(0.635–3.603)	0.350
Clinical stage (IVb vs. IVa)	0.919(0.490–1.724)	0.792
IC regimen; PF vs. TPF	2.091(1.043–4.191)	0.038
IC regimen; TP vs. TPF	2.626(0.490–1.724)	0.037
Distant metastasis-free survival
Age (y) (≥ 45 vs. < 45)	1.103(0.692–1.756)	0.680
Gender(F vs. M)	1.210(0.675–2.171)	0.522
Clinical stage (IVb vs. IVa)	1.762(1.046–2.967)	0.033
IC regimen; PF vs. TPF	2.978(1.566–5.663)	0.001
IC regimen; TP vs. TPF	1.724(1.076–2.763)	0.024

Abbreviations: CI Confidence interval, IC Induction chemotherapy, TPF Taxanes plus cisplatin with fluorouracil, PF Cisplatin with fluorouracil, TP = Taxanes with cisplatin
A Cox proportional hazards regression model was used to detect variables individually without adjustment. All variables were transformed into categorical variables. HRs were calculated for age (years) (≥45 vs. < 45 years), sex (female vs. male), clinical stage (IVb vs. IVa), and IC regimen (PF vs. TPF, TP vs. TPF)

ISSN: 1471-2407